RAPT Therapeutics Strengthens Leadership, Appoints Two Industry Veterans To Its Board Of Directors

RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immunological conditions, has announced the addition of two new members to its board of directors: Dr. Scott Braunstein and Dr. Ashley Dombkowski. As part of their appointments, Dr. Braunstein will join the Board’s Audit Committee, while Dr. Dombkowski will serve on the Nominating and Corporate Governance Committee. Dr. Braunstein brings a strong background in clinical medicine and biotech leadership, with experience in managing company operations and financial oversight. Dr. Dombkowski offers deep expertise in corporate strategy, scientific innovation, and governance, with a focus on life sciences and biotechnology companies.

Brian Wong, M.D., Ph.D., President and CEO of RAPT, said in a statement, “We are excited to welcome Dr. Braunstein and Dr. Dombkowski to our board of directors at this pivotal time and look forward to their guidance as we pursue innovative products for patients with inflammatory and immunologic diseases. Both have extensive industry experience and knowledge that will support our organization as we advance clinical development of RPT904 in food allergy, CSU and potentially other allergic diseases, while also preparing for commercialization in these large, underserved markets.”

Dr. Braunstein stated, “RAPT is at a critical point with an attractive product candidate entering late-stage development. I look forward to helping Brian and the management team capitalize on the tremendous opportunities to bring RPT904 to patients and to grow their I&I pipeline.”

Dr. Dombkowski, mentioned, “I was particularly intrigued by the pipeline-in-a-product potential of RPT904. Food allergy is a large, underserved market with unmet need, and RPT904 has real potential to provide an innovative treatment to meet this need. RAPT will have opportunities to also develop RPT904 in CSU and potentially other allergic diseases, and I am excited to help build this company.”

These appointments come at a pivotal time for RAPT Therapeutics as it continues to advance its lead product candidate, RPT904. RPT904 is a novel, half-life extended monoclonal antibody specifically designed to bind to free human immunoglobulin E (IgE), a key factor involved in triggering allergic diseases. The therapy is currently in Phase 2 clinical trials for chronic spontaneous urticaria and asthma. Additionally, the company plans to begin a Phase 2 trial targeting food allergies later this year. By expanding its board with leaders experienced in both science and corporate governance, RAPT aims to strengthen its strategic direction and support the ongoing development of RPT904 and other immunology-based therapies.